Madrigal Pharmaceuticals, Inc. (MDGL) vs 10x Genomics, Inc. (TXG)
A side-by-side comparison of Madrigal Pharmaceuticals, Inc. and 10x Genomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MDGL
Madrigal Pharmaceuticals, Inc.
$499.96HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
TXG
10x Genomics, Inc.
$83.00HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — MDGL vs TXG
growth of $100 · dividends reinvested · last 7yMDGL +376.7% (+25.0%/yr)TXG +85.3% (+9.2%/yr)MDGL compounded faster over this window
MDGL TXG
MDGL vs TXG: by the numbers
- •MDGL is the larger company ($11.55B vs $10.54B market cap).
- •Both run net losses; TXG's is the smaller (-12.18% vs -25.32% net margin).
Metrics side by side
Valuation
| Metric | MDGL | TXG |
|---|---|---|
| P/S ratio | 9.00 | 17.08 |
| P/B ratio | 22.06 | 12.76 |
| FCF yield | N/A | 1.15% |
Profitability
| Metric | MDGL | TXG |
|---|---|---|
| Gross margin | 91.48% | 70.03% |
| Operating margin | -25.13% | -14.33% |
| Net margin | -25.32% | -12.18% |
| ROE | -62.07% | -9.10% |
| ROIC | -37.02% | -9.57% |
Growth (annualized)
| Metric | MDGL | TXG |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.74% |
| Total return CAGR (5Y) | 44.41% | -7.24% |
Frequently asked
- How have MDGL and TXG total returns compared?
- Over the past 5 years, MDGL delivered 44.41% and TXG delivered -7.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Madrigal Pharmaceuticals ROE10x Genomics ROEMadrigal Pharmaceuticals operating margin10x Genomics operating marginMadrigal Pharmaceuticals revenue growth10x Genomics revenue growthMadrigal Pharmaceuticals free cash flow10x Genomics free cash flow
Madrigal Pharmaceuticals & 10x Genomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.